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Abstract
Background: It is estimated that a total of 120,000 new cancer cases in men and in women in more developed
countries could be avoided if exposure to HPV was prevented. We used the nationwide pool of German
population-based cancer registry data to estimate the burden of HPV-attributable cancer in this population for the
year 2013.
Methods: Incident cases of cervical cancer, squamous cell carcinoma of the anus, oropharynx (OP), as well as of the
vulva, vagina and penis were classified as potentially HPV-associated and identified from the nationwide cancer
registry data-pool. We calculated the incidence and proportions of cancer with potentially HPV-associated
morphologies. Estimation of the HPV-attributable incidence was based on prevalence-estimates of viral DNA in
tumor cells in the respective sites, as provided from the international literature.
Results: From the overall 15,936 incident cases of anogenital and OP cancers in 2013, 6239 female and 1358 male
cancer cases were estimated to be attributable to HPV. The majority of HPV-attributable cases were contributed by
cervical cancer (70.9% of female cancers) and oropharyngeal cancer (46.9% of male cancers).
Conclusions: Even if most HPV-attributable cases were contributed by cervical cancer, anogenital cancer at sites
other than the cervix, and oropharyngeal cancer substantially contribute to the burden of HPV-associated cancer.
Our nationwide cancer registry data-analyses provide the baseline for long-term population-based monitoring of
vaccination-effects on cancer incidence in Germany.
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Background
Persistent infection with Human Papillomavirus (HPV)
is considered a necessary cause in the etiology of virtu-
ally all cases of invasive cervical cancer [1]. In Germany,
4600 women were diagnosed with invasive cervical can-
cer in 2012 [2]. Increasing evidence further suggests
HPV to be causally related to squamous cell carcinomas
of another five cancer sites: the penis, vulva, vagina, anus
and subsites of the oropharynx. It is estimated that a
total of 120,000 new cancer cases in men and in women
in more developed countries could be avoided if expos-
ure to HPV was prevented [3].
Monitoring of HPV-associated disease remains crucial
as two prophylactic HPV-vaccines have been licensed in
Germany in 2006 and are recommended since 2007 by
the German Standing Committee on Vaccination
(STIKO). In 2014, the recommended age for vaccinating
girls was lowered from 12–17 years to 9–14 years [4].
With the introduction of the HPV-vaccine and implemen-
tation in the German vaccination schedule, cervical cancer
might become a largely preventable disease. The current
vaccines are highly effective in preventing infections with
HPV-types 16 and 18, the types that cause most cervical
and anal cancers as well as anogenital pre-cancers [5].
High vaccine efficacy in protection against HPV-16/18 in-
fections in oral sites has been demonstrated [6]. A newly
developed nonavalent HPV-vaccine was recently licensed
in the European Union (EU), which further prevents infec-
tion with HPV-31, 33, 45, 52, and 58 [7] that may cause
about 15% of cervical cancers [8].
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We used the nationwide pool of German population-
based cancer registry data to assess the baseline inci-
dence of HPV-associated cancer in our population for
the year 2013, yet before quantifiable effects from HPV-
vaccination on cancer incidence can be anticipated.
Thus, our analyses provide the basis for a continuous
monitoring of the effects of HPV-vaccination on cancer
incidence at the population-level. This also applies to
HPV-associated cancer in men, as a positive effect from
vaccinating girls on HPV-related outcomes in men is ex-
pected [9]. Potential future discussions on vaccinating
boys against HPV might be triggered by the findings of
this study.
Methods
Classification of potentially HPV-associated cancer and
estimation of the HPV-attributable fraction
Cases of cervical cancer with epithelial, squamous cell,
basal and transitional cell origin, adenocarcinomas and
cystic carcinomas as well as mixed tumors; squamous
carcinoma of the anus and oropharynx, the vulva, vagina
and penis were classified as potentially HPV-associated
carcinoma (Table 1). The International Agency for
Research on Cancer (IARC) established a causal role for
human papillomavirus in a subset of these carcinoma,
defining HPV-associated sites [10].
Pathophysiological knowledge and epidemiologic evi-
dence strongly suggest that the presence of HPV-
infection in tumor material is sufficient to infer that
HPV-infection caused the cancer. Estimation of the
population attributable fraction (PAF) due to HPV was
therefore based on the prevalence of viral DNA in squa-
mous cell carcinoma (SCC) cells in the respective sites,
as provided from the international literature, preferably
from most recent metaanalyses and large tissue sample
studies [1, 11–15]. From the vaginal, penile and anal
cancer studies, the HPV-DNA prevalence in European
invasive SCC was chosen to derive the HPV-
attributional fractions [12–14]. In oropharyngeal cancer,
the HPV-attributional fraction was more specifically de-
rived from the prevalence of the combination of HPV-
DNA positivity, mRNA positivity or positivity for a cell
surrogate marker of HPV-induced carcinogenic trans-
formation (p16INK4a overexpression) - a validated and
widely used HPV-detection algorithm [16]. The orophar-
ynx included the base of tongue, lingual tonsil, overlap-
ping lesions of tongue, tongue not otherwise specified,
soft palate, uvula, overlapping lesions of palate and pal-
ate not otherwise specified, the tonsils, oropharynx, and
other ill-defined sites in lip, oral cavity and pharynx in-
cluding Waldeyer ring. For the HPV-attributable fraction
in vulvar SCC, we used the crude European HPV-
prevalence from HPV-DNA positive/p16INK4a overex-
pressive keratinizing or warty-basaloid vulvar SCC [11].
Namely, all cases of cervical cancer and 88–90% of
anal carcinoma with HPV-associated morphologies were
considered HPV-attributable. An HPV-attributable
proportion of 32% was assumed in penile cancer with
HPV-associated morphologies, whereas 81% of vaginal,
18% of vulvar, and 16% of OP cancer with potentially
HPV-associated morphologies were considered HPV-
attributable (Table 2).
Monitoring of HPV-associated morphology in cancer
registry data
Population-based cancer registration in Germany is or-
ganized by the 16 federal states, six of them merged to a
joint registry for East Germany (including Berlin). Con-
tinuous registration has commenced in 1970 in the
Saarland, but nationwide coverage has not been reached
before 2009, when the population-based cancer registry
of Baden-Württemberg was implemented. According to
our current nationwide estimation, the degree of cancer
registration across Germany is high, and 96% (463,611
cases) of the estimated 482,473 new cancer cases in
2013 have actually been recorded in the registries (data
not shown). For our analyses, we retrieved incident cases
of cervical cancer, penile cancer, vulvar cancer, vaginal
Table 1 HPV-associated cancer sites and morphologic specification
Site ICD-O-3 topography code Potentially HPV-associated morphology ICD-O-3-codes
Cervix C53 All carcinoma (except for melanoma,
mesothelioma, Kaposi sarcoma, lymphoma,
leukemia and other myeloproliferative
malignant disorders)
8010–8671, 8940–8941
Penis C60 Squamous cell carcinoma (SCC) 8050–8084
Vulva C51 SCC 8050–8084
Vagina C52 SCC 8050–8084
Anus C21 (incl. C20 with ICD-O-3 8050–8084,
8120–8131)
SCC 8050–8084
Oropharynx, incl. base of tongue
and tonsils
C01, C02.4–02.9, C05.1–05.9, C09.0–09.9,
C10.0–10.9, C14.0-C14.8
SCC 8050–8084
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cancer, anal cancer, and oropharyngeal cancer from the
nationwide data pool for 2013. Site, behavior and hist-
ology are coded according to the International Classifi-
cation of Diseases for Oncology (ICD-O-3).
For the purpose of monitoring, we provide the number
of newly diagnosed cases, proportions and rates of can-
cer with potentially HPV-associated morphologies.
Morphology codes of potential HPV-association are
shown in Table 1. To correct for missing information on
further morphologic specification of cancer cases (ICD-
O-3 group 800: neoplasms, not otherwise specified), we
redistributed these cases according to the distribution of
morphology codes among those cases with further speci-
fied morphology (by site, gender and 5-year-age-group),
assuming the information on morphology was ‘missing
at random’. Cases notified from death certificate only
(DCO) represented the majority of morphologically not
otherwise specified cases.
Incidence rates from 2013 were age-standardized to
the old European standard population (ASIR). 95% con-
fidence intervals of ASIR were calculated using the bino-
mial approximation according to the recommendation
of IARC [17]. Calculation of the 95% confidence inter-
vals of crude age-specific rates was based on a Poisson-
distribution of the cases.
Results
In 2013, 5564 male incident cases and 10,372 female in-
cident cases of invasive anogenital and oropharyngeal
cancers were registered in Germany. Overall 9573 inci-
dent female cancer cases with potential HPV-associated
site and morphology were extracted from the pooled
data. Amongst them were 6239 incident cases consid-
ered to be attributable to HPV; 4422 cervical cancers
(70.9% of all HPV-attributable female cancer cases), 927
anal cancers, 467 vulvar cancers, 223 vaginal cancers,
and 200 oropharyngeal cancers. Among the 5246 inci-
dent male cancer cases with potential HPV-associated
site and morphology, 1358 cases were attributed to
HPV. Oropharyngeal cancer constituted the largest
group (636 cases; 46.9% of all HPV-attributable male
cancer cases) followed by anal cancer (496 cases) and
penile cancer (225 cases). Table 2 provides the site-
specific results and illustrates our calculations: for vagi-
nal cancer, 386 incident cases were registered in 2013, of
which 275 cases were of HPV-associated morphology. A
proportion of 9.6% (26 cases) of the 275 cases with
HPV-associated morphology were not coded as such,
but redistributed from cases morphologically not other-
wise specified. Applying the assumed PAF of 81% [13],
223 vaginal cancer cases were finally considered attribut-
able to HPV.
Overall, a proportion of 1.6% of an estimated 482,473
new cancer cases in Germany in 2013 was considered
HPV-attributable. The number of 9573 female cancer
cases and 5246 male cancer cases with potential HPV-
associated site and morphology assessed corresponds to
approximately 3.1% (male: 2.1%; female: 4.2%) of the
overall cancer burden in Germany in the same year. The
proportion of incident cases with potentially HPV-
associated morphology that were redistributed from
cases morphologically not otherwise specified ranged be-
tween 3.9% (male anus) and 9.6% (vagina).
The most common cancers in the female and male
population were cervical cancer in women and oropha-
ryngeal cancer in men. Non-cervical anogenital cancer
with HPV-associated morphology were rare in the
German population. Anal cancer with an HPV-associated
Table 2 Incident anogenital and oropharyngeal cancer cases and estimation of HPV-attributable cancer in Germany, 2013
















Cervix 4458 4422 (7.1%) 100% [1] 4422 (70.9%)
Vulva 3015 2596 (4.0%) 18% [11] 467 (7.5%)
Vagina 386 275 (9.6%) 81% [13] 223 (3.6%)
Female anus 1142 1030 (5.0%) 90% [14] 927 (14.9%)
Female oropharynx 1371 1249 (7.5%) 16% [15] 200 (3.2%)
Female overall anogenital &
oropharynx
10,372 9573 (6.1%) 6239 (100%)
Penis 757 704 (6.3%) 32% [12] 225 (16.6%)
Male anus 653 564 (3.9%) 88% [14] 496 (36.5%)
Male oropharynx 4154 3978 (5.8%) 16% [15] 636 (46.9%)
Male overall anogenital &
oropharynx
5564 5246 (5.7%) 1358 (100%)
a proportion of estimated cases with HPV-associated morphology that were not coded as such, but redistributed from cases of not otherwise specified morphology
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morphology was however more common in women than
in men (Table 3).
The age-distribution largely differed by site (Fig. 1a
and b). The largest proportion of patients diagnosed
below the age of 50 years was seen among cervical can-
cer cases (42.9%). Almost half of all anal cancer cases
and female oropharyngeal cancer patients were 50–
64 years of age (39.6% of female anal cancer patients,
41.2% of male anal cancer patients, and 47.0% of female
oropharyngeal cancer patients respectively). Penile, vul-
var and vaginal cancer patients were comparably older
at diagnosis. The age distribution of male oropharyngeal
cancer patients closely resembled the one of female oro-
pharyngeal cancer patients (Fig. 1b): 9.1% of men were
younger than 50 years (in females: 9.3%), 53.5% were
aged 50 to 64 years (in females: 47.0%), 33.7% were aged
65 years to 79 years (in females 34.5%) and 3.7% were
80 years or older (in females: 9.4%).
Correspondingly, crude incidence rates (IR) of cervical
cancer were highest in the age groups of 35–49 years
and 50–64 years (16.5 per 100,000 and 14.8 per 100,000,
respectively) and hereafter declined (Table 4). IR of vul-
var, vaginal, anal, and penile cancer increased with in-
creasing age. For oropharyngeal cancer, incidence rates
peaked at ages 50–64 years both in men (IR: 24.8 per
100,000) and in women (IR: 6.7 per 100,000) and here-
after declined (Table 4).
Discussion
Overall, the 6239 incident female HPV-attributable can-
cer cases and 1358 incident male HPV-attributable can-
cer cases relate to approximately 1.6% HPV-attributable
incident cancer cases of the 482,473 new cancer cases in
Germany in the same year.
Similar estimates have been reported in other popula-
tions of the western world [18, 19]. Despite methodo-
logical differences in selection of HPV-prevalence
estimates, different contribution of cancers related to
other risk factors (such as tobacco smoking or alcohol
consumption) on the overall and site specific cancer bur-
den, and potentially different degrees of completeness of
cancer registry data, our estimates are comparable with
recent 2010 figures from the United Kingdom (UK)
(1.6%) [18], Australia (1.5%) [19], and the approximately
2.0% HPV-associated cancers in Europe, proposed in a
recent synthesis on the global burden of infection-
associated cancer [3]. The latter was based on the
GLOBOCAN-database provided by IARC, which pro-
vides incidence figures by cancer site and country, but
not further specified by morphology. Hence, our more
conservative approach of applying the HPV-attributable
fractions on cases that were of potential HPV-associated
morphology only, resulted in somewhat lower estimates
of HPV-related disease burden compared to the
European estimates provided by DeMartel et al. [3].
An aspect that limits precision of our results is intro-
duced by using HPV-attributable fractions from the
international literature and their application to our na-
tional incidence.
Population-based cancer registries neither collect in-
formation on HPV in tumor tissue nor on other individ-
ual risk factors such as smoking. Hence, the proportion
of HPV-attributable cases, which were derived mostly
from recent metaanalyses or large case series, might be
over- or underestimated. As prevalence of HPV is likely
to vary by country, age, gender (in case of oropharyngeal
and anal cancer) and time, the actual HPV-prevalence
among cancer cases in Germany might deviate from the
prevalence estimates we presumed. In oropharyngeal
cancer, previous studies from Germany that were in-
cluded in a recent metaanalysis [20] and one recent
German study based on a clinical sample reported
higher HPV-prevalence as the European estimate of 16%
provided by Castellsague et al. [15, 21]. Differences in
methods of HPV-testing usually hamper precise
comparisons of HPV-prevalence over time and study
population – an important advantage of the highly stan-
dardized study protocol and the single-centre HPV-
DNA detection and genotyping in the study by
Castellsagué et al. The authors further describe an in-
creasing proportion of HPV-positive oropharyngeal can-
cer cases over time (worldwide): only about 10% of
oropharyngeal cancer cases diagnosed in the 1990s were
HPV-DNA-positive and mRNA-positive/p16-positive. In
oropharyngeal cancer cases diagnosed in 2010–2012,
one third was HPV-DNA-positive and mRNA-positive/
p16-positive [15]. It is not clear if HPV-prevalence in the
German population is increasing, but recent data indir-
ectly suggests that the observed increase of OP-SCC in
the younger population in countries with declining
smoking prevalence might be explained by increasing
Table 3 Age-standardized incidence rate (ASIR) of cancer in men
and women with HPV-associated morphology, Germany 2013
Men Women
ASIR 95% CI ASIR 95% CI
Overall anogenital 2.3 2.2–2.4 14.8 14.4–15.1
Cervix – – 8.9 8.6–9.2
Penis 1.2 1.1–1.3 – –
Vulva – – 3.7 3.6–3.9
Vagina – – 0.4 0.3–0.4
Anus 1.1 1.0–1.2 1.7 1.6–1.8
Oropharynx 7.6 7.4–7.9 2.2 2.0–2.3
Age-standardized incidence rates (European standard population) and
corresponding 95% confidence intervals (95%CI) per 100,000 population;
HPV-associated morphology codes (ICD-O-3): 8010–8671, 8940–8941 (cervix),
8050–8084 (penis, vulva, vagina, anus, oropharynx)
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Fig. 1 Distribution of age-groups in female (a) and male (b) cancer with HPV-associated morphology, Germany 2013
Table 4 Age-specific incidence-rates (95% confidence intervals) of female and male cancer with HPV-associated morphology by
age-groups, Germany 2013
35–49 years 50–64 years 65–79 years ≥80 years
IR 95% CI IR 95% CI IR 95% CI IR 95% CI
Women Cervix 16.5 15.6–17.4 14.8 14.0–15.6 12.4 11.6–13.3 14.1 12.8–15.6
Vulva 3.3 2.9–3.7 6.4 5.9–7.0 15.0 14.1–16.0 24.3 22.6–26.2
Vagina 0.2 0.1–0.3 0.7 0.5–0.9 1.7 1.4–2.1 2.7 2.1–3.4
Anus 1.5 1.3–1.8 4.7 4.2–5.2 4.7 4.2–5.2 5.8 4.9–6.7
Oropharynx 1.3 1.1–1.5 6.7 6.2–7.3 6.4 5.8–7.1 4.1 3.4–4.9
Men Penis 0.6 0.4–0.8 2.2 1.9–2.5 5.8 5.2–6.4 8.8 7.3–10.4
Anus 1.1 0.9–1.4 2.7 2.4–3.1 2.9 2.5–3.4 4.0 3.1–5.2
Oropharynx 4.0 3.6–4.5 24.8 23.8–25-9 23.4 22.1–24.7 10.0 8.5–11.8
Age-specific incidence rates (IR) and corresponding 95% confidence intervals (95%CI) per 100,000 population
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HPV-prevalence [22–24]. Given the changing epidemi-
ology of HPV-positive oropharyngeal cancer over time,
our numbers might underestimate the actual HPV-
attributable fraction. Rising HPV-prevalence may also
partly explain the increasing trends in vulva cancer
which we recently described for Germany [25].
The quality of epidemiological cancer registry data
limits registry-based studies in general, and also needs to
be considered in our study: An aspect of uncertainty is
introduced by potentially incomplete registration of inci-
dent cases in some registries, leading to underestima-
tion. However, nine German federal states had achieved
sufficient data quality and completeness to be included
in the IARC publication “Cancer in five continents
(CI5)” for the years 2003–2007, which can be regarded
as a reference for high quality registries [26]. Since 2009,
incident cancer cases are registered nationwide and
quality has well improved. A comparison of the esti-
mated nationwide incidence indicates that we might
have also underestimated the incidence of anogenital
and oropharyngeal cancer by up to 5%. The relatively
high proportion of cases notified from death certificate
only (DCO) (3–10% by cancer site considered in our
analysis) similarly suggests certain underreporting in
German cancer registries. Another source of bias was in-
troduced by missing information on morphologically not
otherwise specified cancer in some cases: overall, 6.1% of
morphologically HPV-associated cases in women and
5.7% in men were estimated due to missing information
on morphology (including DCO).
In recent studies of penile, anal, vaginal and vulvar
cancer, the histological term “warty” or “basaloid/warty”
carcinoma has been used to characterize HPV-associated
carcinoma [11–14]. Only recently, this term was intro-
duced in the updated World Health Organization
(WHO)-classification of tumours of the penis, and a
new code (8054/3) for this entity was suggested [27].
The former code for “not otherwise specified keratiniz-
ing squamous cell carcinoma (8071/3 keratinizing SCC,
NOS)” was omitted. At present, the cancer registry data
based on ICD-O-3 classification does not yet provide
this specific information. This limitation also applies to
the issue of monitoring time trends at the other ano-
genital sites. The PAF for basaloid/warty cancer would
be much higher than the PAFs we applied (e.g. an attrib-
utable fraction of 57% in warty/basaloid vulvar SCC
compared to 18% in all invasive vulvar cancer [11]),
however applied to fewer cases with HPV-associated
morphology. Further morphology-, age- and site-specific
analyses of pathology records are in preparation to verify
our literature-based assumption on the HPV-attributable
proportions in SCC.
Due to missing information on site specific HPV-
prevalence in the general German population [28] our
PAF-estimates are based upon HPV-prevalence in tumor
tissue from international studies and therefore should be
considered an approximation. Prevalence in tumor tissue
might not necessarily be causally related to cancer devel-
opment, especially if other risk factors are present.
Tobacco-smoking constitutes another major risk factor
for anogenital and oropharyngeal cancer, as well as im-
munodeficiency with HIV-positivity or immunosuppres-
sion following organ transplantation [29–32].
It should be mentioned, that our estimates only take
invasive tumors into account, while especially for the
cervix, a large number of high-grade dysplastic lesions
contribute to the HPV-related disease burden, demand-
ing invasive treatment. Similar to other published esti-
mates on HPV-related disease burden, we did not
consider these cases in our analyses.
HPV-associated anogenital cancer and oropharyngeal
cancer substantially contribute to the burden of cancer.
In the United States of America (US), cancer with HPV-
associated site and morphology account for 2% of male
cancer cases and 3.3% of female cancer cases [33]. Our
estimates of 5246 incident male cases and 9573 female
cases relate to 2.1% and 4.2%, respectively. Moreover, in
the Western world, the incidence in HPV-associated
cancers in younger age-groups increases [22, 25, 34–36].
Successfully implemented HPV-vaccinations programs
should reverse these trends during the next decades.
For long-term monitoring of time trends (over 2–4 de-
cades), a focus on cancer sites with high HPV-
attributable fractions in younger age-groups (35–
49 years) might be reasonable, though effects can first be
expected to become observable in the more distant fu-
ture: In Germany, HPV vaccination commenced in 2007
for 12–17 year old girls. As the oldest vaccinated women
from the birth cohort of 1990 will not reach age 35 until
2023, it will be 2038 before the 35–49 age-group con-
sists entirely of potentially vaccinated women.
The attributable fraction method may however not be
suitable for monitoring time trends in the incidence of
HPV-attributable cancers for sites with low attributional
fractions, such as vulvar cancer and the oropharyngeal
cancers group. Using vulvar cancer as an example, 18%
of all vulvar cancers diagnosed in 2013 were attributed
to HPV infection; 82% were attributed to other causes. If
HPV vaccination decreases the incidence of HPV-
attributable vulvar cancer in future years, this will hardly
become apparent in the overall estimates, and the effect
of the vaccine especially in low-PAF cancers in absolute
terms will be underestimated without regular monitoring
of the prevalence of HPV DNA in cancer cells. A de-
creasing proportion of cancer with HPV-associated
morphology at respective sites would be expected. The
newly emerging clinical cancer registries in Germany
(according to the Law on the Further Development of
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the Early Detection of Cancer and Quality Assurance
Through Clinical Cancer Registries [37]) might provide
another anchor for concomitant projects to continuously
monitor the cancer incidence and HPV-prevalence in
cancer for short and medium term effects from HPV-
vaccination in Germany in the near future.
Conclusions
Our estimates of the cancer burden at HPV-related sites
along with the HPV-attributable fractions provide a
baseline assessment of the HPV-related cancer burden
in Germany and contribute to future evaluation of long-
term HPV-vaccination effects on the population level.
With population-based clinical cancer-registration, fu-
ture monitoring of HPV-associated cancer in Germany
is feasible with more accuracy and precision than using
global estimates.
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